ICBS, McCoy Enterprises LLC, Connell Associates LLC enter into joint health care venture in 11 billion dollar industryLast update: 3/11/2008 11:28:00 AMNJ, CARY NC and MONTREAL, March 11, 2008 /PRNewswire-FirstCall via COMTEX/ -- ICBS Limited (Pink Sheets :ICBM) a business development and management firm located in New York and Canada and McCoy Enterprises LLC of New Jersey, a life science product development company, and Connell Associates LLC of Cary NC, a Pharmaceutical and Biotechnology Consulting organization announced today that they have entered into a joint venture under the name of PharmaDerm LLC. PharmaDerm LLC will be focused on licensing, developing and commercializing their portfolio of pharmaceutical and biotechnologies. Pharmaderm will work with the US Food and Drug Administration (FDA) and The Health Protection Branch of Canada to gain regulatory approval of products for commercialization of new treatments for Skin Disorders, Chronic Wounds, Severe Burns, Dermatology. Connell Associates, LLC is a Pharmaceutical and Biotechnology consulting company and has helped launch over 25 major drugs. They are in the Sales Management, Marketing and commercial consulting arena. "PharmaDerm LLC will be the perfect match to utilize the specific expertise of the corporations." Says Joe Connell, President and CEO of Connell Associates, LLC. "McCoy Enterprises, LLC is proud to be part of this multi-national venture to bring quality products to the people who need them" says Randall McCoy, President of McCoy Enterprises, LLC. "The strength brought in by Connell Associates and ICBS, Limited ensures success of commercializing proven products." ICBS specializes in mergers and acquisitions (M&A) advisory services and invests in selective businesses with potential for high growth." This joint venture has brought together a perfect team to take advantage of this vast market" said Garth McIntosh, President & CEO of ICBS. NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.
